Details for Patent: 9,415,053
✉ Email this page to a colleague
Which drugs does patent 9,415,053 protect, and when does it expire?
Patent 9,415,053 protects XARELTO and is included in one NDA.
Protection for XARELTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-three patent family members in thirty-four countries.
Summary for Patent: 9,415,053
| Title: | Solid, orally administrable pharmaceutical composition |
| Abstract: | The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin- -5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases. |
| Inventor(s): | Benke; Klaus (Bergisch Gladbach, DE) |
| Assignee: | Bayer Intellectual Property GmbH (Monheim, DE) |
| Application Number: | 14/250,863 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,415,053 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Process; Dosage form; Use; |
Drugs Protected by US Patent 9,415,053
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-004 | Oct 11, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-001 | Jul 1, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-002 | Nov 4, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-003 | Nov 4, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,415,053
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 103 55 461 | Nov 27, 2003 |
International Family Members for US Patent 9,415,053
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 047844 | ⤷ Sign Up | |||
| Argentina | 104840 | ⤷ Sign Up | |||
| Austria | 385782 | ⤷ Sign Up | |||
| Australia | 2004305226 | ⤷ Sign Up | |||
| Brazil | PI0416404 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
